Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas’ Vasomotor Symptom Treatment Fezolinetant Smashes Primary Goals in US PIIb Study
Astellas Pharma’s investigational postmenopausal vasomotor symptoms (VMS) treatment fezolinetant (development code: ESN364) met the four US FDA-recommended endpoints in a PIIb clinical study in the US, the company said on March 27. Fezolinetant, a selective neurokinin-3 (NK3) receptor antagonist, works…
To read the full story
Related Article
- PIII Gets Underway for Astellas’ Hot Flash Drug Fezolinetant
August 7, 2019
BUSINESS
- Sandoz to Sell, Distribute G-Lasta Biosimilar in Japan
August 26, 2026
- Astellas Starts Global PIII of ASP2138 in Gastric Cancer
August 26, 2026
- Chugai Files Vamikibart in Japan for Uveitic Macular Edema
August 26, 2026
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…